Breakthrough Pain in Elderly Patients with Cancer: Treatment Options
- 450 Downloads
The prevalence of pain is high in the elderly and increases with the occurrence of cancer. Pain treatment is challenging because of age-related factors such as co-morbidities, and over half of the patients with cancer pain experience transient exacerbation of pain that is known as breakthrough pain (BTP). As with background pain, BTP should be properly assessed before being treated. The first step to be taken is optimizing around-the-clock analgesia with expert titration of the painkiller. Rescue medication should then be provided as per the requested need, while at the same time preventing identified potential precipitating factors. In the elderly, starting treatment with a lower dose of analgesics may be justified because of age-related physiological changes such as decreased hepatic and renal function. Whenever possible, oral medication should be provided prior to a painful maneuver. In the case of unpredictable BTP, immediate rescue medication is mandatory and the subcutaneous route is preferred unless patient-controlled analgesia via continuous drug infusion is available. Recently, transmucosal preparations have appeared in the medical armamentarium but it is not yet known whether they represent a truly efficient alternative, although their rapid onset of activity is already well recognized. Adjuvant analgesics, topical analgesics, anesthetic techniques and interventional techniques are all valid methods to help in the difficult management of pain and BTP in elderly patients with cancer. However, none has reached a satisfying scientific level of evidence as to nowadays make the development of undisputed best practice guidelines possible. Further research is therefore on the agenda.
KeywordsPregabalin Cancer Pain Rescue Medication Breakthrough Pain Oral Transmucosal Fentanyl Citrate
No sources of funding were used to assist in the preparation of this article. Sophie Pautex, Nicole Vogt-Ferrier and Gilbert B. Zulian have no conflict of interests to report.
- 11.Davies AN. The management of breakthrough cancer pain. Br J Nurs. 2011;20(803–4):806–7.Google Scholar
- 18.Laverty D. Assessment. In: Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press; 2006. p. 23–30.Google Scholar
- 28.Gannon C, Davies A. Non-opioid drugs. In: Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press; 2006. p. 83–96.Google Scholar
- 34.Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006;(1):CD004311.Google Scholar
- 42.Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nystrom C, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005;59:249–53.PubMedCentralPubMedCrossRefGoogle Scholar
- 46.Sophie Lussier D, Portenoy RK. Adjuvant analgesics in pain management. In: Doyle D, Hanks G, Cherny N, Calman K, editors. Oxford textbook of palliative medicine. 3rd ed. Oxford: Oxford University Press; 2004. p. 349–78.Google Scholar
- 53.Farquhar-Smith P. Cancer-related bone pain. In: Davies A, editor. Anaesthetic/interventional techniques. Oxford: Oxford Press; 2007. p. 85–97.Google Scholar